ArticleFrontiers in immunology2022
Human Hepatic CD56
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Immunopathogenesis of antibody-mediated rejection in liver transplantation.Frontiers in immunology · 2026Review
- A pre-emptive risk model for acute rejection in liver transplantation: an immunopharmacologic biomarker panel combining CD4+ T-cell profiling and tacrolimus exposure.Frontiers in immunology · 2026Article
- The dual role of T cells in solid organ transplant rejection and immune tolerance.Frontiers in immunology · 2026Review
- Understanding Liver Transplantation Outcomes Through the Lens of Its Tissue-resident Immunobiome.Transplantation · 2025Review
- Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation.Cancer medicine · 2025Review
- Role of liver-resident NK cells in liver immunity.Hepatology international · 2025Review
- Cd16Aging and disease · 2025Article
- A 41-marker 37-color full spectrum flow cytometry panel for the deep immunophenotyping of human peripheral and liver natural killer cells.Frontiers in immunology · 2025Article
- Human tissue-resident NK cells in the lung have a higher glycolytic capacity than non-tissue-resident NK cells in the lung and blood.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Mechanisms of Tolerance Induction in Liver Transplantation: Lessons Learned from Fetomaternal Tolerance, Autoimmunity and Tumor Immunity.International journal of molecular sciences · 2024Review
- Tissue-resident memory NK cells: Homing in on local effectors and regulators.Immunological reviews · 2024Review
- Protective and pathogenic functions of innate lymphoid cells in transplantation.Clinical and experimental immunology · 2023Review
- CD160 receptor in CLL: Current state and future avenues.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver-resident CD56
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.